Golimumab is a human monoclonal antibody administered the moment per month by subcutaneous injection. While it's got the same protection and efficacy profile to other TNFi, golimumab is fewer effective than other TNFi in people who have failed many biological treatment plans. The most recent therapeutic method of RA authorised https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/